Abbas Mirshafiey

List of Publications by Year
in descending order

186	3,565	134610	242451
papers	citations	34 h-index	47 g-index

189	189	189	5556
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Evaluation of the acute and 28-day sub-acute intravenous toxicity of Î±-<scp>l</scp>-guluronic acid (ALG; G2013) in mice. Drug and Chemical Toxicology, 2022, 45, 151-160.	1.2	7
2	A controlled, randomized phase II clinical trial for efficacy and safety evaluation of mannuronic acid in secondary progressive form of multiple sclerosis. International Journal of Neuroscience, 2022, 132, 403-412.	0.8	2
3	Tau and amyloid beta differentially affect the innate immune genes expression in Drosophila models of Alzheimerâ€™s disease and Î²- D Mannuronic acid (M2000) modulates the dysregulation. Gene, 2022, 808, 145972.	1.0	4
4	Evaluation of G2013 (Î±â€Lâ€guluronic acid) efficacy on PCâ€3 cells through inhibiting the expression of inflammatory factors. Clinical and Experimental Pharmacology and Physiology, 2022, 49, 254-263.	0.9	2
5	Evaluating Mannuronic Acid Effect on Gene Expression Profile of Inflammatory Mediators in Rheumatoid Arthritis Patients. Iranian Journal of Allergy, Asthma and Immunology, 2022, 21, 44-54.	0.3	2
6	Immunophenotypic and functional analysis of lymphocyte subsets in common variable immunodeficiency patients without monogenic defects. Scandinavian Journal of Immunology, 2022, 96, e13164.	1.3	7
7	Evaluation of the oral administration of Î±â€<scp>l</scp>â€guluronic acid on COXâ€1 and <scp>COX</scp>â€2 gene expression profile in ankylosing spondylitis patients. Drug Development Research, 2021, 82, 296-301.	1.4	2
8	Î²-D-Mannuronic Acid (M2000) as a Landmark in Pharmacology. Current Drug Discovery Technologies, 2021, 18, 47-57.	0.6	4
9	Influence of Î²-D-mannuronic Acid, as a New Member of Non-steroidal Anti- Inflammatory Drugs Family, on the Expression Pattern of Chemokines and their Receptors in Rheumatoid Arthritis. Current Drug Discovery Technologies, 2021, 18, 65-74.	0.6	5
10	Anti-tumor effect of M2000 (Î²-<scp>d</scp>-mannuronic acid) on the expression of inflammatory molecules in the prostate cancer cell. Immunopharmacology and Immunotoxicology, 2021, 43, 419-430.	1.1	3
11	The effects of guluronic acid (G2013), a new emerging treatment, on inflammatory factors in nonalcoholic steatohepatitis patients under in vitro conditions. Immunopharmacology and Immunotoxicology, 2021, 43, 562-570.	1.1	2
12	Lymphocytes subsets in correlation with clinical profile in CVID patients without monogenic defects. Expert Review of Clinical Immunology, 2021, 17, 1041-1051.	1.3	6
13	Evaluation of the Effect of Mannuronic Acid as a Novel NSAID With Immunosuppressive Properties on Expression of SOCS1 , SOCS3 , SHIP1 , and TRAF6 Genes and Serum Levels of ILâ€6 and TNFâ€Î± in Patients With Multiple Sclerosis. Journal of Clinical Pharmacology, 2021, 61, 1303-1310.	1.0	2
14	Assessment of Biochemical Determinants in Multiple Sclerosis Patients Following the Oral Administration of Î²-D-Mannuronic Acid (M2000). Current Drug Discovery Technologies, 2021, 18, e17092020186049.	0.6	2
15	The evaluation of safety property and apoptotic efficacy of Î±-L-Guluronic Acid (G2013), as a novel NSAID, under in vitro examination on L929 and hepatocellular carcinoma cell lines. Recent Advances in Inflammation & Allergy Drug Discovery, 2021, 15, .	0.4	0
16	Efficient roles of miR-146a in cellular and molecular mechanisms of neuroinflammatory disorders: An effectual review in neuroimmunology. Immunology Letters, 2021, 238, 1-20.	1.1	13
17	Cytokine storm in the pathophysiology of COVID-19: Possible functional disturbances of miRNAs. International Immunopharmacology, 2021, 101, 108172.	1.7	19
18	The effects of mannuronic acid on ILâ€1Î², ILâ€17A, STAT1 and STAT3 gene expression and TLR2 and TLR4 molecules in multiple sclerosis. Journal of Clinical Pharmacology, 2021, , .	1.0	2

#	Article	IF	Citations
19	Immunopharmacological effect of Î²â€<scp>d</scp>â€mannuronic acid (M2000), as a new immunosuppressive drug, on gene expression of miRâ€155 and its target molecules (SOCS1, SHIP1) in a clinical trial on rheumatoid arthritis patients. Drug Development Research, 2020, 81, 295-304.	1.4	14
20	Effects of guluronic acid, as a new NSAID with immunomodulatory properties on IL-17, RORÎ³t, IL-4 and GATA-3 gene expression in rheumatoid arthritis patients. Immunopharmacology and Immunotoxicology, 2020, 42, 22-27.	1.1	10
21	The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients. Recent Patents on Inflammation and Allergy Drug Discovery, 2020, 14, 69-77.	3.9	5
22	The Effect of Î²-<scp>d</scp>-Mannuronic Acid in Animal Model of Epilepsy. Natural Product Communications, 2020, 15, 1934578X2092003.	0.2	0
23	A comprehensive review on miR-146a molecular mechanisms in a wide spectrum of immune and non-immune inflammatory diseases. Immunology Letters, 2020, 227, 8-27.	1.1	32
24	The role of Î²-<scp>d</scp>-mannuronic acid, as a new non-steroidal anti-inflammatory drug on expression of miR-146a, IRAK1, TRAF6, NF-Î°B and pro-inflammatory cytokines following a clinical trial in rheumatoid arthritis patients. Immunopharmacology and Immunotoxicology, 2020, 42, 228-236.	1.1	7
25	Mannuronic Acid in Lowâ€Risk and Intermediateâ€1â€Risk Myelodysplastic Syndromes. Journal of Clinical Pharmacology, 2020, 60, 879-888.	1.0	0
26	Efficacy of Î²-D-Mannuronic Acid [M2000] on the Pro-Apoptotic Process and Inflammatory-Related Molecules NFÎ°B, IL-8 and Cd49d using Healthy Donor PBMC. Current Drug Discovery Technologies, 2020, 17, 225-232.	0.6	2
27	The Oral Administration Effect of Drug Mannuronic Acid (M2000) on Gene Expression of Matrix and Tissue Inhibitor of Metalloproteinases in Rheumatoid Arthritis Patients. Current Drug Discovery Technologies, 2020, 17, 704-710.	0.6	1
28	Anti-Diabetic and Angio-Protective Effect of Guluronic Acid (G2013) as a New Nonsteroidal Anti-Inflammatory Drug in the Experimental Model of Diabetes. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 446-452.	0.6	1
29	The Effects of G2013 (Î±-L-guluronic Acid) in a Pentylenetetrazole-induced Kindling Animal Model of Epilepsy. Innovations in Clinical Neuroscience, 2020, 17, 9-12.	0.1	0
30	Anti-diabetic effect of Î²-<scp>D</scp>-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property on insulin production, blood glucose, and inflammatory markers in the experimental diabetes model. Archives of Physiology and Biochemistry, 2019, 125, 435-440.	1.0	11
31	Effects of guluronic acid (G2013) on gene expression of TLR2, TLR4, MyD88, TNF-Î± and CD52 in multiple sclerosis under in vitro conditions. Immunopharmacology and Immunotoxicology, 2019, 41, 586-590.	1.1	5
32	The role of T helper 17 and regulatory T cells in tumor microenvironment. Immunopharmacology and Immunotoxicology, 2019, 41, 16-24.	1.1	31
33	Vitamin D downregulates key genes of diabetes complications in cardiomyocyte. Journal of Cellular Physiology, 2019, 234, 21352-21358.	2.0	18
34	The Inhibitory Role of M2000 (Î²-D-Mannuronic Acid) on Expression of Toll-like Receptor 2 and 4 in HT29 Cell Line. Recent Patents on Inflammation and Allergy Drug Discovery, 2019, 13, 57-65.	3.9	1
35	A randomized, controlled, phase <scp>II</scp> clinical trial of Î²â€Dâ€mannuronic acid (M2000) in preâ€surgical breast cancer patients at early stage (T1â€T2). Clinical and Experimental Pharmacology and Physiology, 2019, 46, 527-532.	0.9	5
36	Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway. International Journal of Biological Macromolecules, 2019, 133, 436-445.	3.6	58

#	Article	IF	Citations
37	The safety and efficacy of Guluronic acid (G2013) in ankylosing spondylitis: A randomized controlled parallel clinical trial. Pharmacological Reports, 2019, 71, 393-398.	1.5	5
38	International multicenter randomized, placebo-controlled phase III clinical trial of Î²-d-mannuronic acid in rheumatoid arthritis patients. Inflammopharmacology, 2019, 27, 911-921.	1.9	13
39	Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties. Immunologic Research, 2019, 67, 108-115.	1.3	5
40	A randomized clinical trial for the assessment of the efficacy and safety of guluronic acid (G2013) in patients with rheumatoid arthritis. Immunopharmacology and Immunotoxicology, 2019, 41, 95-101.	1.1	7
41	An in vitro assessment for evaluating the efficiency of Î²â€•d â€mannuronic acid (M2000) in myelodysplastic syndrome. Journal of Cellular Physiology, 2019, 234, 12971-12977.	2.0	5
42	The Toll-like Receptor 2 (TLR2)-related Immunopathological Responses in the Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Iranian Journal of Allergy, Asthma and Immunology, 2019, 18, 230-250.	0.3	15
43	The Immunomodulatory Role of G2013 (α-L-Guluronic Acid) on the Expression of TLR2 and TLR4 in HT29 cell line. Current Drug Discovery Technologies, 2019, 16, 91-95.	0.6	7
44	Effect of Î²-D-Mannuronic Acid (M2000) on Oxidative Stress Enzymesâ€™ Gene Using Healthy Donor Peripheral Blood Mononuclear Cells for Evaluating the Anti-Aging Property. Current Drug Discovery Technologies, 2019, 16, 265-271.	0.6	7
45	Antagonistic Property of G2013 (Î±-L-Guluronic Acid) on Gene Expression of MyD88, Tollip, and NF-ÎºB in HEK293 TLR2 and HEK293 TLR4. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2019, 19, 144-149.	0.6	2
46	Vitamin D suppresses cellular pathways of diabetes complication in liver. Iranian Journal of Basic Medical Sciences, 2019, 22, 690-694.	1.0	5
47	Effect of Guluronic Acid (G2013), As a New Anti-inflammatory Drug on Gene Expression of Pro-inflammatory and Anti-inflammatory Cytokines and Their Transcription Factors in Rheumatoid Arthritis Patients. Iranian Journal of Allergy, Asthma and Immunology, 2019, 18, 639-648.	0.3	2
48	The Effect of Vitamin D on Cellular Pathways of Diabetic Nephropathy. Reports of Biochemistry and Molecular Biology, 2019, 7, 217-222.	0.5	8
49	Vaccine potential of LenA and LcpA proteins of in combination with heat-labile enterotoxin, B subunit (LTB). Iranian Journal of Microbiology, 2019, 11, 39-47.	0.8	3
50	The Anti-tumoral Effect of Î²-D-Mannuronic Acid (M2000) as a Novel NSAID on Treg Cells Frequency and MMP-2, MMP-9, CCL22 and TGFÎ²1 Gene Expression in Pre-surgical Breast Cancer Patients. Iranian Journal of Allergy, Asthma and Immunology, 2019, 18, 80-90.	0.3	1
51	Interleukin-1Î² and interleukin-6 in Common Variable Immunodeficiency and their association with subtypes of B cells and response to the Pneumovax-23 vaccine. European Cytokine Network, 2019, 30, 123-129.	1.1	2
52	Oral administration effects of Î²-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis. Biomedicine and Pharmacotherapy, 2018, 100, 495-500.	2.5	19
53	A phase I/II randomized, controlled, clinical trial for assessment of the efficacy and safety of Î²-d-mannuronic acid in rheumatoid arthritis patients. Inflammopharmacology, 2018, 26, 737-745.	1.9	17
54	Cardioprotective effect of Î²-<scp>d</scp>-mannuronic acid (M2000) as a novel NSAID on gene expression of oxLDL scavenger receptors in the experimental diabetic model. Immunopharmacology and Immunotoxicology, 2018, 40, 284-289.	1.1	11

#	Article	IF	Citations
55	Antiâ€inflammatory and antiâ€tumor effects of Î±-l-guluronic acid (G2013) on cancer-related inflammation in a murine breast cancer model. Biomedicine and Pharmacotherapy, 2018, 98, 793-800.	2.5	43
56	Effects of guluronic acid (G2013) on SHIP1, SOCS1 induction and related molecules in TLR4 signaling pathway. International Immunopharmacology, 2018, 55, 323-329.	1.7	17
57	Antiâ€angiogenesis effect of Î²â€Dâ€mannuronic acid (M2000) as a novel NSAID with immunosuppressive properties under experimental model. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 370-376.	0.9	10
58	The effect of 1, 25(OH)2 D3 (calcitriol) alone and in combination with all-trans retinoic acid on RORÎ³t, IL-17, TGF-Î², and FOXP3 gene expression in experimental autoimmune encephalomyelitis. Nutritional Neuroscience, 2018, 21, 210-218.	1.5	19
59	The effects of Î²-d-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte/macrophage, J774 cell line. Inflammopharmacology, 2018, 26, 375-384.	1.9	10
60	Targeting of circulating Th17 cells by Î²-D-mannuronic acid (M2000) as a novel medication in patients with rheumatoid arthritis. Inflammopharmacology, 2018, 26, 57-65.	1.9	13
61	Combination treatment of docosahexaenoic acid (DHA) and all-trans-retinoic acid (ATRA) inhibit IL-17 and RORÎ³t gene expression in PBMCs of patients with relapsing-remitting multiple sclerosis. Neurological Research, 2018, 40, 11-17.	0.6	16
62	Evaluation of the efficacy and safety of Î²-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I/II clinical trial. International Immunopharmacology, 2018, 54, 112-117.	1.7	26
63	Autoimmunity and its association with regulatory T cells and B cell subsets in patients with common variable immunodeficiency. Allergologia Et Immunopathologia, 2018, 46, 127-135.	1.0	27
64	Evaluation of the Effect of Î±-L-Guluronic Acid (G2013) on COX-1, COX-2 Activity and Gene Expression for Introducing this Drug as a Novel NSAID with Immunomodulatory Property. Recent Patents on Inflammation and Allergy Drug Discovery, 2018, 12, 162-168.	3.9	14
65	The imbalance of circulating T helper subsets and regulatory T cells in patients with LRBA deficiency: Correlation with disease severity. Journal of Cellular Physiology, 2018, 233, 8767-8777.	2.0	22
66	Therapeutic effects of pegylated-interferon-Î±2a in a mouse model of multiple sclerosis. Central-European Journal of Immunology, 2018, 43, 9-17.	0.4	2
67	The effect of lipopolysaccharide on the expression level of immunomodulatory and immunostimulatory factors of human amniotic epithelial cells. BMC Research Notes, 2018, 11, 343.	0.6	12
68	Immunomodulatory Effect of G2013 (Î±-L-Guluronic Acid) on the TLR2 and TLR4 in Human Mononuclear Cells. Current Drug Discovery Technologies, 2018, 15, 123-131.	0.6	17
69	The Anti-Migraine Effects of M2000 (Î²-D-Mannuronic Acid) on a Patient with Rheumatoid Arthritis: Case Report. Current Clinical Pharmacology, 2018, 12, 127-130.	0.2	3
70	Modification of Sexual Hormones in Rheumatoid Arthritis Patients by M2000 (Î²-D-mannuronic Acid) as a Novel NSAID with Immunosuppressive Property. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2018, 18, 530-536.	0.6	5
71	Dual Effects of Cell Free Supernatants from Lactobacillus acidophilus and Lactobacillus rhamnosus GG in Regulation of MMP-9 by Up-Regulating TIMP-1 and Down-Regulating CD147 in PMADifferentiated THP-1 Cells. Cell Journal, 2018, 19, 559-568.	0.2	23
72	Vitamin D3 Induces Gene Expression of Ox-LDL Scavenger Receptors in Streptozotocin-Induced Diabetic Rat Aortas: New Insight into the Role of Vitamin D in Diabetic Atherosclerosis. Reports of Biochemistry and Molecular Biology, 2018, 6, 170-177.	0.5	3

#	Article	IF	Citations
73	The Profile of Toll-like Receptor 2 (TLR2), TLR4 and Their Cytosolic Downstream Signaling Pathway in Common Variable Immunodeficiency (CVID) Patients. Iranian Journal of Allergy, Asthma and Immunology, 2018, 17, 188-200.	0.3	3
74	Abnormality of regulatory T cells in common variable immunodeficiency. Cellular Immunology, 2017, 315, 11-17.	1.4	36
75	Preclinical and pharmacotoxicology evaluation of Î±-<scp>l</scp>-guluronic acid (G2013) as a non-steroidal anti-inflammatory drug with immunomodulatory property. Immunopharmacology and Immunotoxicology, 2017, 39, 59-65.	1.1	18
76	Pharmacological effects of Î²-d-mannuronic acid (M2000) on miR-146a, IRAK1, TRAF6 and NF-ÎºB gene expression, as target molecules in inflammatory reactions. Pharmacological Reports, 2017, 69, 479-484.	1.5	23
77	Targeting of crosstalk between tumor and tumor microenvironment by Î²â€Ð mannuronic acid (M2000) in murine breast cancer model. Cancer Medicine, 2017, 6, 640-650.	1.3	37
78	Anti-aging effects of M2000 (Î²-D-mannuronic acid) as a novel immunosuppressive drug on the enzymatic and non-enzymatic oxidative stress parameters in an experimental model. Journal of Basic and Clinical Physiology and Pharmacology, 2017, 28, 249-255.	0.7	17
79	Effects of M2000 (D-Mannuronic Acid) on Learning, Memory Retrieval, and Associated Determinants in a Rat Model of Alzheimerâ€™s Disease. American Journal of Alzheimer's Disease and Other Dementias, 2017, 32, 12-21.	0.9	13
80	Introduction of Î²- d -mannuronic acid (M2000) as a novel NSAID with immunosuppressive property based on COX-1/COX-2 activity and gene expression. Pharmacological Reports, 2017, 69, 1067-1072.	1.5	19
81	Therapeutic effects of D-aspartate in a mouse model of multiple sclerosis. Journal of Food and Drug Analysis, 2017, 25, 699-708.	0.9	14
82	An in vitro evaluation of anti-aging effect of guluronic acid (G2013) based on enzymatic oxidative stress gene expression using healthy individuals PBMCs. Biomedicine and Pharmacotherapy, 2017, 90, 262-267.	2.5	21
83	M2000 (Î²â€Ðâ€Mannuronic Acid) as a Novel Antagonist for Blocking the <scp>TLR</scp>2 and <scp>TLR</scp>4 Downstream Signalling Pathway. Scandinavian Journal of Immunology, 2017, 85, 122-129.	1.3	28
84	The potent suppressive effect of Î²- d -mannuronic acid (M2000) on molecular expression of the TLR/NF-kB Signaling Pathway in ankylosing spondylitis patients. International Immunopharmacology, 2017, 52, 191-196.	1.7	18
85	Immunomodulatory effects of M2000 (Î²-D-Mannuronic acid) on TNF-Î±, IL-17 and FOXP3 gene expression in patients with inflammatory bowel disease. International Immunopharmacology, 2017, 51, 107-113.	1.7	6
86	The Effect of Lactobacillus acidophilus PTCC 1643 on Cultured Intestinal Epithelial Cells Infected with Salmonella enterica serovar Enteritidis. Osong Public Health and Research Perspectives, 2017, 8, 54-60.	0.7	10
87	Effects of β-D-mannuronic acid, as a novel non-steroidal anti-inflammatory medication within immunosuppressive properties, on IL17, RORγt, IL4 and GATA3 gene expressions in rheumatoid arthritis patients. Drug Design, Development and Therapy, 2017, Volume11, 1027-1033.	2.0	24
88	The Potent Inhibitory Effect of Î²-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis. Current Drug Discovery Technologies, 2017, 14, 206-214.	0.6	11
89	A Review on Defects of Dendritic Cells in Common Variable Immunodeficiency. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2017, 17, 100-113.	0.6	8
90	The Immunomodulatory Effect of Trichophyton Rubrum Exoantigens in the Treatment of Experimental Septic Arthritis. Open Microbiology Journal, 2017, 11, 72-82.	0.2	1

#	Article	IF	Citations
91	The Biology of Î²-D-mannuronic acid (M2000) on Human Dendritic Cell Based on MicroRNA-155 and MicroRNA-221. Current Drug Discovery Technologies, 2017, 14, 53-58.	0.6	2
92	The Role of M2000 as an Anti-inflammatory Agent in Toll-Like Receptor 2/microRNA-155 Pathway. Avicenna Journal of Medical Biotechnology, 2017, 9, 8-12.	0.2	8
93	Efficacy and Safety of G2013 as a Novel Immunosuppressive Agent on Differentiation, Maturation and Function of Human Dendritic Cells. Iranian Journal of Public Health, 2017, 46, 216-221.	0.3	9
94	Hematological Improvement of Patients with Active Rheumatoid Arthritis by Î²-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property. Iranian Journal of Allergy, Asthma and Immunology, 2017, 16, 433-442.	0.3	9
95	Anti-inflammatory Property of Î²-D-Mannuronic Acid (M2000) on Expression and Activity of Matrix Metalloproteinase-2 and -9 through CD147 Molecule in Phorbol Myristate Acetate-differentiated THP-1 Cells. Iranian Journal of Allergy, Asthma and Immunology, 2017, 16, 443-451.	0.3	7
96	Anti-Aging Property of G2013 Molecule as a Novel Immunosuppressive Agent on Enzymatic and Non-Enzymatic Oxidative Stress Determinants in Rat Model. Current Drug Discovery Technologies, 2016, 13, 25-33.	0.6	22
97	Autoimmunity in Primary Antibody Deficiencies. International Archives of Allergy and Immunology, 2016, 171, 180-193.	0.9	40
98	Autoimmunity in primary T-cell immunodeficiencies. Expert Review of Clinical Immunology, 2016, 12, 989-1006.	1.3	15
99	Cellular and molecular mechanisms of immune dysregulation and autoimmunity. Cellular Immunology, 2016, 310, 14-26.	1.4	39
100	Inhibitory effect of G2013 molecule as a novel immunomodulatory agent, on miR-155 gene expression in HEK-Blue hTLR4 cell line. European Journal of Inflammation, 2016, 14, 86-92.	0.2	10
101	The role of toll-like receptors in B-cell development and immunopathogenesis of common variable immunodeficiency. Expert Review of Clinical Immunology, 2016, 12, 195-207.	1.3	19
102	EBV and vitamin D status in relapsing-remitting multiple sclerosis patients with a unique cytokine signature. Medical Microbiology and Immunology, 2016, 205, 143-154.	2.6	21
103	The Safety Property of Î²-D-Mannuronic Acid (M2000) as a Novel Immunosuppressive Agent on Differentiation, Maturation and Function of Human Dendritic Cells. Current Drug Discovery Technologies, 2016, 13, 164-169.	0.6	3
104	Hydroxycitric acid ameliorates inflammation and oxidative stress in mouse models of multiple sclerosis. Neural Regeneration Research, 2016, 11, 1610.	1.6	19
105	Comparison of the Detection Limits of the Culture and PCR Methods for the Detection of Clostridium difficile, Clostridium perfringens, Campylobacter jejuni, and Yersinia enterocolitica in Human Stool. Archives of Pediatric Infectious Diseases, 2016, 5, .	0.1	6
106	In Vitro Effects of Propranolol on T Helper Type 1 Cytokine Profile in Human Leukemic T Cells. International Journal of Hematology-Oncology and Stem Cell Research, 2016, 10, 99-105.	0.3	6
107	The Potential Role of T Helper Cell 22 and IL-22 in Immunopathogenesis of Multiple Sclerosis. Innovations in Clinical Neuroscience, 2016, 13, 30-6.	0.1	11
108	Role of Proangiogenic Factors in Immunopathogenesis of Multiple Sclerosis. Iranian Journal of Allergy, Asthma and Immunology, 2016, 15, 1-12.	0.3	20

#	Article	IF	Citations
109	Quantitative Evaluation of BAFF, HMGB1, TLR 4 AND TLR 7 Expression in Patients with Relapsing Remitting Multiple Sclerosis. Iranian Journal of Allergy, Asthma and Immunology, 2016, 15, 75-81.	0.3	9
110	Monogenic Auto-inï¬,ammatory Syndromes: A Review of the Literature. Iranian Journal of Allergy, Asthma and Immunology, 2016, 15, 430-444.	0.3	6
111	Tâ€helper 22 cells as a new player in chronic inflammatory skin disorders. International Journal of Dermatology, 2015, 54, 880-888.	0.5	33
112	The Role of Inflammatory Mediators in the Pathogenesis of Alzheimerâ€™s Disease. Sultan Qaboos University Medical Journal, 2015, 15, e305-316.	0.3	60
113	HLA antigens and anti-sperm antibody production in Iranian vasectomized men. Journal of Biomedical Research, 2015, 29, 87-90.	0.7	3
114	Effect of probiotics on the expression of Barrettâ€™s oesophagus biomarkers. Journal of Medical Microbiology, 2015, 64, 348-354.	0.7	15
115	Therapeutic effects of dasatinib in mouse model of multiple sclerosis. Immunopharmacology and Immunotoxicology, 2015, 37, 287-294.	1.1	20
116	Th1 Cytokine Production Induced by Lactobacillus acidophilus in BALB/c Mice Bearing Transplanted Breast Tumor. Jundishapur Journal of Microbiology, 2015, 8, e17354.	0.2	35
117	New therapeutic approach by G2013 in experimental model of multiple sclerosis. Acta Neurologica Belgica, 2015, 115, 259-266.	0.5	35
118	Silibinin, up-regulates chemokine receptor expression in MDA-MB-231 breast cancer cell line. Bangladesh Journal of Medical Science, 2015, 14, 190-195.	0.1	2
119	Kombucha tea ameliorates experimental autoimmune encephalomyelitis in mouse model of multiple sclerosis. Food and Agricultural Immunology, 2015, 26, 782-793.	0.7	19
120	Preclinical assessment ofÎ²-<scp>d</scp>-mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug. Immunopharmacology and Immunotoxicology, 2015, 37, 535-540.	1.1	48
121	A Live Vector Expressing HPV16 L1 Generates an Adjuvant-Induced Antibody Response In-vivo. Iranian Journal of Cancer Prevention, 2015, 8, e3991.	0.7	5
122	IL-22 Produced by T helper Cell 22 as a New player in the Pathogenesis of Immune Thrombocytopenia. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2015, 15, 242-250.	0.6	8
123	The Newly Identified T Helper 22 Cells Lodge in Leukemia. International Journal of Hematology-Oncology and Stem Cell Research, 2015, 9, 143-54.	0.3	3
124	Effect of Genistein and L-Carnitine and Their Combination on Gene Expression of Hepatocyte HMG-COA Reductase and LDL Receptor in Experimental Nephrotic Syndrome. Iranian Journal of Public Health, 2015, 44, 1339-47.	0.3	4
125	Th22 Cells Contribution in Immunopathogenesis of Rheumatic Diseases. Iranian Journal of Allergy, Asthma and Immunology, 2015, 14, 246-54.	0.3	11
126	Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: A randomized controlled clinical trial. Nutritional Neuroscience, 2014, 17, 16-20.	1.5	46

#	Article	IF	Citations
127	Does Lipoic Acid Consumption Affect the Cytokine Profile in Multiple Sclerosis Patients: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. NeuroImmunoModulation, 2014, 21, 291-296.	0.9	54
128	Calcium Intervention Ameliorates Experimental Model of Multiple Sclerosis. Oman Medical Journal, 2014, 29, 185-189.	0.3	19
129	Positive and negative effects of prostaglandins in <scp>A</scp>lzheimer's disease. Psychiatry and Clinical Neurosciences, 2014, 68, 50-60.	1.0	22
130	The role of leukotrienes in immunopathogenesis of rheumatoid arthritis. Modern Rheumatology, 2014, 24, 225-235.	0.9	31
131	The potential role of angiogenic factors in rheumatoid arthritis. International Journal of Rheumatic Diseases, 2014, 17, 369-383.	0.9	48
132	The potential role of iNKT cells in experimental allergic encephalitis and multiple sclerosis. Immunopharmacology and Immunotoxicology, 2014, 36, 105-113.	1.1	10
133	The Potential Role of Chemokines in Alzheimerâ€™s Disease Pathogenesis. American Journal of Alzheimer's Disease and Other Dementias, 2014, 29, 415-425.	0.9	63
134	The Significance of Matrix Metalloproteinases in the Immunopathogenesis and Treatment of Multiple Sclerosis = Ø£Ù‡Ù…ÙŠØ© Ø§Ù„Ø£Ù†Ø²ÙŠÙ…Ø§Øª Ø§Ù„Ù…Ø¹Ø¯Ù†ÙŠØ© Ø§Ù„Ù…ØµÙ„Ù„Ø© Ù„Ù„Ø¨Ø±ÙˆØªÙŠÙ† ÙÙŠ Ø¢Ø·Ù	0.3	55
135	Soy protein and genistein improves renal antioxidant status in experimental nephrotic syndrome. Nefrologia, 2014, 34, 483-90.	0.2	35
136	Receptor Tyrosine Kinase and Tyrosine Kinase Inhibitors: New Hope for Success in Multiple Sclerosis Therapy. Innovations in Clinical Neuroscience, 2014, 11, 23-36.	0.1	13
137	Alteration in frequency and function of CD4âºCD25âºFOXP3âº regulatory T cells in patients with immune thrombocytopenic purpura. Iranian Journal of Allergy, Asthma and Immunology, 2014, 13, 85-92.	0.3	24
138	Altered pattern of NaÃ¯ve and memory B cells and B1 cells in patients with chronic granulomatous disease. Iranian Journal of Allergy, Asthma and Immunology, 2014, 13, 157-65.	0.3	9
139	Effects of imatinib mesylate in mouse models of multiple sclerosis and in vitro determinants. Iranian Journal of Allergy, Asthma and Immunology, 2014, 13, 198-206.	0.3	18
140	Th17 Cells in Immunopathogenesis and treatment of rheumatoid arthritis. International Journal of Rheumatic Diseases, 2013, 16, 243-253.	0.9	93
141	The role of leukotrienes in immunopathogenesis of rheumatoid arthritis. Modern Rheumatology, 2013, , 1.	0.9	9
142	Evaluation of CD4+CD25+FOXP3+ regulatory T cells function in patients with common variable immunodeficiency. Cellular Immunology, 2013, 281, 129-133.	1.4	48
143	Anti-citrullinated protein antibodies and their clinical utility in rheumatoid arthritis. International Journal of Rheumatic Diseases, 2013, 16, 379-386.	0.9	49
144	The Neglected Role of Histamine in Alzheimerâ€™s Disease. American Journal of Alzheimer's Disease and Other Dementias, 2013, 28, 327-336.	0.9	54

#	Article	IF	Citations
145	Properties of Immature Myeloid Progenitors with Nitric-Oxide-Dependent Immunosuppressive Activity Isolated from Bone Marrow of Tumor-Free Mice. PLoS ONE, 2013, 8, e64837.	1.1	8
146	Imatinib Mesylate: An Innovation in Treatment of Autoimmune Diseases. Recent Patents on Inflammation and Allergy Drug Discovery, 2013, 7, 259-267.	3.9	27
147	Influenza Virus-like Particle Containing Two Different Subtypes of Hemagglutinin Confers Protection in Mice Against Lethal Challenge With A/PR8 (H1N1) and A/HK (H3N2) Viruses. Iranian Red Crescent Medical Journal, 2013, 15, 75-82.	0.5	13
148	Regulatory T Cells as a Therapeutic Tool To Induce Solid-Organ Transplant Tolerance: Current Clinical Experiences. Experimental and Clinical Transplantation, 2013, 11, 379-387.	0.2	6
149	Novel therapeutic approach by nicotine in experimental model of multiple sclerosis. Innovations in Clinical Neuroscience, 2013, 10, 20-5.	0.1	6
150	Autoantigens and autoantibodies in multiple sclerosis. Iranian Journal of Allergy, Asthma and Immunology, 2013, 12, 292-303.	0.3	8
151	The Role of Different Subsets of Regulatory T Cells in Immunopathogenesis of Rheumatoid Arthritis. Arthritis, 2012, 2012, 1-16.	2.0	78
152	Increased production of nitric oxide by neutrophils from patients with chronic granulomatous disease on interferon-gamma treatment. International Immunopharmacology, 2012, 12, 689-693.	1.7	21
153	Siglec-8 and Siglec-F, the new therapeutic targets in asthma. Immunopharmacology and Immunotoxicology, 2012, 34, 721-726.	1.1	18
154	The deviated balance between regulatory T cell and Th17 in autoimmunity. Immunopharmacology and Immunotoxicology, 2012, 34, 727-739.	1.1	44
155	The potential role of proinflammatory and antiinflammatory cytokines in Alzheimer disease pathogenesis. Immunopharmacology and Immunotoxicology, 2012, 34, 881-895.	1.1	58
156	Natural Killer Cells and Their Role in Rheumatoid Arthritis: Friend or Foe?. Scientific World Journal, The, 2012, 2012, 1-10.	0.8	40
157	Conversion of Calcineurin Inhibitors With Mammalian Target of Rapamycin Inhibitors After Kidney Transplant. Experimental and Clinical Transplantation, 2012, 11, 12-16.	0.2	0
158	The immunopathogenic role of reactive oxygen species in Alzheimer disease. Iranian Journal of Allergy, Asthma and Immunology, 2012, 11, 203-16.	0.3	38
159	Regulatory T-cell as orchestra leader in immunosuppression process of multiple sclerosis. Immunopharmacology and Immunotoxicology, 2011, 33, 545-567.	1.1	44
160	Randomized controlled trial using vitamins E and D supplementation in atopic dermatitis. Journal of Dermatological Treatment, 2011, 22, 144-150.	1.1	128
161	Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs. Recent Patents on Inflammation and Allergy Drug Discovery, 2011, 5, 66-80.	3.9	12
162	Prostaglandins in pathogenesis and treatment of multiple sclerosis. Immunopharmacology and Immunotoxicology, 2010, 32, 543-554.	1.1	37

#	Article	IF	Citations
163	Immunopharmacological role of the Leukotriene Receptor Antagonists and inhibitors of leukotrienes generating enzymes in Multiple Sclerosis. Immunopharmacology and Immunotoxicology, 2010, 32, 219-227.	1.1	21
164	Therapeutic Effect of EDTA in Experimental Model of Multiple Sclerosis. Immunopharmacology and Immunotoxicology, 2010, 32, 321-326.	1.1	12
165	Histamine and histamine receptors in pathogenesis and treatment of multiple sclerosis. Neuropharmacology, 2010, 59, 180-189.	2.0	81
166	Therapeutic approach by Aloe vera in experimental model of multiple sclerosis. Immunopharmacology and Immunotoxicology, 2010, 32, 410-415.	1.1	9
167	Polyunsaturated Fatty Acids, Microflora and Colitis. Annals of Nutrition and Metabolism, 2009, 55, 325-325.	1.0	13
168	TGF-Î² as a promising option in the treatment of multiple sclerosis. Neuropharmacology, 2009, 56, 929-936.	2.0	58
169	Antioxidant therapy in multiple sclerosis. Immunopharmacology and Immunotoxicology, 2009, 31, 13-29.	1.1	86
170	Alginate and Its Comonomer Mannuronic Acid: Medical Relevance as Drugs. Microbiology Monographs, 2009, , 229-260.	0.3	9
171	Therapeutic Effect of Artemether in an Experimental Model of Nephrosis. Pharmaceutical Biology, 2008, 46, 639-646.	1.3	0
172	The role of reactive oxygen species in immunopathogenesis of rheumatoid arthritis. Iranian Journal of Allergy, Asthma and Immunology, 2008, 7, 195-202.	0.3	106
173	Treatment of Experimental Nephrotic Syndrome with Artesunate. International Journal of Toxicology, 2007, 26, 373-380.	0.6	8
174	Venom therapy in multiple sclerosis. Neuropharmacology, 2007, 53, 353-361.	2.0	60
175	Therapeutic Approach by a Novel Designed Anti-Inflammatory Drug, M2000, in Experimental Immune Complex Glomerulonephritis. Immunopharmacology and Immunotoxicology, 2007, 29, 49-61.	1.1	35
176	Novel Promising Therapeutic Agents in Multiple Sclerosis. Recent Patents on Inflammation and Allergy Drug Discovery, 2007, 1, 218-224.	3.9	7
177	Treatment of experimental immune complex glomerulonephritis by sodium alginate. Vascular Pharmacology, 2005, 43, 30-35.	1.0	10
178	Chemoprevention by Pyrimethamine. Immunopharmacology and Immunotoxicology, 2005, 27, 233-240.	1.1	5
179	Novel Immunosuppressive Therapy by M2000 in Experimental Multiple Sclerosis. Immunopharmacology and Immunotoxicology, 2005, 27, 255-265.	1.1	51
180	Bee Venom, Immunostimulant or Immunosuppressor? Insight into the Effect on Matrix Metalloproteinases and Interferons. Immunopharmacology and Immunotoxicology, 2005, 27, 671-681.	1.1	10

#	Article	IF	Citations
181	Artemether: A New Therapeutic Strategy in Experimental Rheumatoid Arthritis. Immunopharmacology and Immunotoxicology, 2005, 27, 615-630.	1.1	32
182	M2000: a revolution in pharmacology. Medical Science Monitor, 2005, 11, PI53-63.	0.5	20
183	Mâ€2000, as a New Antiâ€inflammatory Molecule in Treatment of Experimental Nephrosis. Immunopharmacology and Immunotoxicology, 2004, 26, 611-619.	1.1	19
184	Chemopreventive effect of M2000, a new anti-inflammatory agent. Medical Science Monitor, 2004, 10, PI105-9.	0.5	21
185	TREATMENT OF EXPERIMENTAL NEPHROSIS BY CULTURE FILTRATE OFCRYPTOCOCCUS NEOFORMANSVAR. GATTII (CneF). Immunopharmacology and Immunotoxicology, 2002, 24, 349-364.	1.1	5
186	Novel therapeutic approach by culture filtrate of Cryptococcus neoformans var. gattii (CneF) in experimental immune complex glomerulonephritis. General Pharmacology, 2000, 34, 311-319.	0.7	11